Ramon Varcoe, MBBS, co-principal investigator for the LIFE-BTK trial, discussed the results with Cardiovascular Business at TCT 2023. "I can't wait to start using these in my patients. It's going to make a huge difference."

Firas Zahr, MD, spoke to Cardiovascular Business about early data on the Medtronic TMVR device. His team's study is designed to follow patients for a total of five years.

Browse through some of the many highlights from TCT 2023 in San Francisco.

There were some concerns among researchers after one study suggested iFR may increase the risk of mortality. New data presented at TCT 2023, however, showed that the two technologies are linked to similar outcomes. 

The mitral valve has been an especially challenging target for transcatheter interventions, but there are reasons to think key breakthroughs are on the horizon. We talked to Kendra Grubb, MD, about this and other ongoing trends at TCT 2023. 

Kendra Grubb, MD, one of the country's leading experts on cardiac surgery, discussed what she tells her patients when they ask if TAVR is better than SAVR for treating severe aortic stenosis. 

IVUS was especially effective when treating patients with a complex coronary anatomy, researchers found. 

Could this late-breaking clinical trial from TCT 2023 be a sign of things to come in the years ahead? Samir Kapadia, MD, explored the topic in a new interview. 

Intravascular lithotripsy therapy to break up calcified coronary lesions will now be reimbursed at a higher rate under new in-hospital codes the went into effect Oct. 1.

Robert Yeh, MD, detailed the importance of the pivotal AGENT IDE trial, which focused on the use of a paclitaxel-coated balloon to treat in-stent restenosis. 

Michael Reardon, MD, discussed his team's late-breaking results at TCT 2023 in San Francisco. 

New data presented at TCT 2023 suggest the Evoque tricuspid valve replacement system could make a significant impact on the lives of patients with severe TR.